MedTrace Logo

A Study of Bupivacaine Liposome Injection in the Treatment of Pain After Thoracoscopic Surgery

NCT06529432 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2026-03-12

No results posted yet for this study

Summary

The objective of this study is to evaluate the efficacy, safety, and tolerability of bupivacaine liposomes for paravertebral nerve block in the treatment of thoracoscopic postoperative pain, and to evaluate the relevant human pharmacokinetics.

Conditions

  • Local Analgesia Via Nerve Block

Interventions

DRUG

Bupivacaine Liposome Injection

Bupivacaine Liposome Injection Low Dose or Moderate Dose or High Dose

DRUG

Bupivacaine Hydrochloride Injection

Bupivacaine Hydrochloride Injection Low Dose or Moderate Dose or High Dose

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-03
Primary Completion
2026-11-30
Completion
2026-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06529432 on ClinicalTrials.gov